Chemistry and Industry - Risperdal approved for troubled teens
The US Food and Drug Administration (FDA) has approved the use of Risperdal for treatment of two psychiatric disorders in children and adolescents.
Risperdal was approved to treat schizophrenia in 13-17 year olds and bipolar disorder in 10-17 year olds. Approval was granted after two six-eight week trials involving more than 500 children and adolescents. Risperdal is the only drug approved to treat schizophrenia in children and only the second drug available to treat bipolar disorders, after lithium, in adolescents. The drug is manufactured by US pharmaceutical Janssen which is part of the Johnson & Johnson group.
Related Results
RisperdalRisperdal approvalRisperdal okayRisperdal doseRisperdal cleared
[ILLUSTRATION OMITTED]
COPYRIGHT 2007 Society of Chemical Industry
COPYRIGHT 2008 Gale, Cengage Learning
